207 related articles for article (PubMed ID: 15101732)
21. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
[TBL] [Abstract][Full Text] [Related]
22. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
23. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
24. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
25. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
26. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Vega-Ruiz A; O'Brien S; Cortes J; Kebriaei P; Thomas D; Kantarjian H; Ravandi F
Leuk Res; 2008 Sep; 32(9):1468-71. PubMed ID: 18355919
[TBL] [Abstract][Full Text] [Related]
27. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
[No Abstract] [Full Text] [Related]
28. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
29. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
31. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
32. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
33. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
34. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
36. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
37. Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Myojo T; Hino N
Intern Med; 2004 Feb; 43(2):126-30. PubMed ID: 15005255
[TBL] [Abstract][Full Text] [Related]
38. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
Park MJ; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Jeong JW; Ahn JY; Park J
Ann Lab Med; 2014 May; 34(3):247-51. PubMed ID: 24790915
[No Abstract] [Full Text] [Related]
39. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
Jin Huh H; Won Huh J; Myong Seong C; Lee M; Soon Chung W
Am J Hematol; 2003 Nov; 74(3):218-20. PubMed ID: 14587058
[TBL] [Abstract][Full Text] [Related]
40. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
